GlassScriptPhysician profile
Chloe Dean-Biltekoff
NPI 1275264418
$4,639.62
in general payments reported to CMS, 2019-2025
38 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $828 · 2023: $2,581 · 2024: $930 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,811.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $1,207.88 | 2023-2025 | Gocovri, Apokyn, Gocovri |
| Biogen, INC. | $472.35 | 2022-2023 | Vumerity, Tysabri, Spinraza |
| Alexion Pharmaceuticals, INC. | $410.74 | 2022-2023 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $322.03 | 2022-2023 | |
| Abbvie INC. | $285.98 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $211.84 | 2023 | Nuedexta |
| Genentech USA, INC. | $137.97 | 2022-2023 | Ocrevus |
| Catalyst Pharmaceuticals, INC. | $136.99 | 2022-2023 | Fycompa, Firdapse |
| Emd Serono, INC. | $124.99 | 2023 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $121.57 | 2022-2023 | Austedo Xr, Austedo |
| Inspire Medical Systems, INC. | $102.22 | 2023 | Inspire |
| Supernus Pharmaceuticals, INC. | $92.24 | 2025 | Qelbree |
| Alnylam Pharmaceuticals INC. | $90.19 | 2022-2023 | Onpattro |
| Csl Behring | $72.08 | 2022-2023 | Hizentra |
| Neurocrine Biosciences, INC. | $71.51 | 2023 | Ingrezza, Ongentys |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $62.45 | 2024 | Cd Horizon Spinal System |
| Genzyme Corporation | $59.36 | 2022-2023 | |
| Kyowa Kirin, INC. | $57.95 | 2022-2023 | Nourianz |
| Axsome Therapeutics, INC. | $53.56 | 2023 | Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $47.84 | 2022 | |
| Genentech, INC. | $42.26 | 2023 | Ocrevus |
| Acorda Therapeutics, INC | $42.17 | 2023 | Inbrija, Ampyra |
| Jazz Pharmaceuticals INC. | $41.21 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $40.72 | 2022-2023 | Rytary |
| Lilly USA, LLC | $40.52 | 2023 | Reyvow, Emgality |
| Tanabe Pharma America, INC. | $38.36 | 2022-2023 | |
| Argenx US, INC. | $32.74 | 2023 | Vyvgart |
| Lundbeck LLC | $32.44 | 2023 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $27.61 | 2023 | Gammagard |
| Sk Life Science, INC. | $24.85 | 2023 | |
| Harmony Biosciences LLC | $24.06 | 2023 | Wakix |
| Janssen Pharmaceuticals, INC | $19.09 | 2023 | Ponvory |
| Abbott Laboratories | $17.83 | 2024 | Proclaim |
| Pfizer INC. | $15.85 | 2023 | |
| Ucb, INC. | $15.77 | 2023 | Briviact |
| Acadia Pharmaceuticals INC | $15.64 | 2025 | Nuplazid |
| Celgene Corporation | $14.01 | 2023 | Zeposia |
| Amylyx Pharmaceuticals, INC. | $12.75 | 2023 | Relyvrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Dean-Biltekoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.